Compare Stocks → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:EPIXNASDAQ:ETONNASDAQ:GNPXNASDAQ:MBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsEPIXESSA Pharma$6.08-2.7%$7.91$2.58▼$11.67$268.98M1.76124,935 shs17,513 shsETONEton Pharmaceuticals$3.41-0.9%$3.72$2.42▼$5.81$87.60M1.1966,850 shs130,776 shsGNPXGenprex$2.41-0.8%$3.02$2.09▼$42.40$5.06M-0.5465,731 shs17,641 shsMBIOMustang Bio$0.27+0.6%$0.74$0.22▼$8.17$2.83M1.75182,160 shs41,514 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%+3.45%EPIXESSA Pharma-7.27%-10.07%-19.15%-40.08%+123.21%ETONEton Pharmaceuticals-7.66%-8.40%-3.78%-22.11%-2.14%GNPXGenprex+4.29%+2.97%-20.85%-46.94%-92.55%MBIOMustang Bio-6.60%-7.78%-60.50%-79.84%-94.05%Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AEPIXESSA Pharma1.7632 of 5 stars3.52.00.00.01.13.30.0ETONEton Pharmaceuticals2.3675 of 5 stars3.55.00.00.02.30.80.0GNPXGenprex4.2299 of 5 stars3.55.00.04.70.00.81.3MBIOMustang Bio1.4296 of 5 stars3.55.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AEPIXESSA Pharma3.00Buy$16.50171.38% UpsideETONEton Pharmaceuticals3.00Buy$9.00163.93% UpsideGNPXGenprex3.00Buy$10.00314.94% UpsideMBIOMustang Bio3.00Buy$17.256,244.24% UpsideCurrent Analyst RatingsLatest GNPX, MBIO, CYAD, ETON, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00EPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AETONEton Pharmaceuticals$31.64M2.77N/AN/A$0.60 per share5.68GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)ETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%8/8/2024 (Estimated)GNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)Latest GNPX, MBIO, CYAD, ETON, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024ETONEton Pharmaceuticals-$0.02-$0.03-$0.01-$0.03$8.30 million$7.97 million 3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/AEPIXESSA PharmaN/A40.7440.74ETONEton PharmaceuticalsN/A1.651.60GNPXGenprexN/A2.312.31MBIOMustang BioN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AEPIXESSA Pharma75.12%ETONEton Pharmaceuticals27.86%GNPXGenprex14.05%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%EPIXESSA Pharma14.70%ETONEton Pharmaceuticals13.16%GNPXGenprex11.54%MBIOMustang Bio2.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableGNPXGenprex262.10 million1.86 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableGNPX, MBIO, CYAD, ETON, and EPIX HeadlinesSourceHeadlineMustang Bio Announces Closing of $4 Million Public Offeringglobenewswire.com - May 2 at 4:01 PMLSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issuesmsn.com - April 30 at 4:49 PMMustang Bio Announces Pricing of $4 Million Public Offeringglobenewswire.com - April 29 at 8:00 PMWorcester biotech down to 11 employees after asset sale stallsbizjournals.com - April 22 at 7:47 PMWorcester biopharmaceutical firm Mustang Bio to lay off 81% of staffwbjournal.com - April 18 at 1:45 PMBiotech cites federal review of deal with Chinese firm in latest staff cutsbizjournals.com - April 16 at 9:03 AMMustang Bio stock tumbles 27% amid news of mass layoffsmsn.com - April 15 at 5:59 PMMustang Bio announces major workforce reductioninvesting.com - April 14 at 11:56 AMMustang Bio to Cut Global Headcount by 81%marketwatch.com - April 12 at 8:56 PMMustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseasesprecisionmedicineonline.com - March 29 at 3:32 PMMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesglobenewswire.com - March 28 at 9:00 AMMustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trialfiercebiotech.com - March 12 at 1:35 PMMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 11 at 4:05 PMCAR T-Cell Therapy Shows Activity in Subgroup of Brain Tumor Patientstechnologynetworks.com - March 8 at 8:10 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Gliomatmcnet.com - March 7 at 9:09 AMWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarketmarkets.businessinsider.com - March 7 at 9:09 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Gliomaglobenewswire.com - March 7 at 7:30 AMMustang Bio Inc (MBIO)uk.investing.com - February 13 at 2:36 PMMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conferencefinance.yahoo.com - January 11 at 9:29 AMMustang Bio Inc MBIOmorningstar.com - January 6 at 12:54 AMMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:10 PMMBIO Mustang Bio, Inc.seekingalpha.com - December 22 at 10:10 AMMustang Bio: Departure Of Directors Or Certain Officers; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officerscbonds.com - December 14 at 5:42 PMMustang Bio files to sell 2.74M shares of common stock for holdersmsn.com - December 12 at 1:26 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.